title: Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
abstract: BACKGROUND
  SPD476 (MMX mesalazine), is a novel, once daily, high-strength mesalazine formulation (1.2 g/tablet) that utilizes Multi Matrix System (MMX) technology to delay and extend delivery of the active drug throughout the colon.
  
  
  OBJECTIVE
  To assess the safety and efficacy of MMX mesalazine in patients with mild-to-moderately active ulcerative colitis, in a pilot, phase II, randomized, multicentre, double-blind, parallel-group, dose-ranging study (SPD476-202).
  
  
  METHODS
  Thirty-eight patients with mild-to-moderately active ulcerative colitis were randomized to MMX mesalazine 1.2, 2.4 or 4.8 g/day given once daily for 8 weeks. Remission ulcerative colitis-disease activity index (UC-DAI) < or =1, a score of 0 for rectal bleeding and stool frequency, and > or =1 -point reduction in sigmoidoscopy score from baseline was the primary end point.
  
  
  RESULTS
  Week 8 remission rates were 0%, 31% and 18% of patients receiving MMX mesalazine 1.2, 2.4 and 4.8 g/day respectively. No statistically significant difference in remission was observed between treatment groups. MMX mesalazine 2.4 and 4.8 g/day groups demonstrated greater improvement in overall UC-DAI and component scores from baseline, compared with the 1.2 g/day group.
  
  
  CONCLUSIONS
  MMX mesalazine given as 2.4 or 4.8 g/day once daily is well tolerated and effective for the treatment of mild-to-moderately active ulcerative colitis.
authors.affiliation: Department of Gastroenterology, Imelda General Hospital, Imelda GI Clinical Research Center, Imeldalaan, Bonheiden, Belgium. geert.dhaens@imelda.be
authors.forename: G
authors.initials: G
authors.lastname: D'Haens
authors.forename: D
authors.initials: D
authors.lastname: Hommes
authors.forename: L
authors.initials: L
authors.lastname: Engels
authors.forename: F
authors.initials: F
authors.lastname: Baert
authors.forename: L
authors.initials: L
authors.lastname: van der Waaij
authors.forename: P
authors.initials: P
authors.lastname: Connor
authors.forename: J
authors.initials: J
authors.lastname: Ramage
authors.forename: O
authors.initials: O
authors.lastname: Dewit
authors.forename: M
authors.initials: M
authors.lastname: Palmen
authors.forename: D
authors.initials: D
authors.lastname: Stephenson
authors.forename: R
authors.initials: R
authors.lastname: Joseph
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine